Skip to main content
Explore URMC


S-CitAD - Escitalopram for Agitation in Alzheimer's Disease

Research Question:
Will the antidepressant medicine, escitalopram, help people who have Alzheimer's disease (AD) with agitation?

Basic Study Information

Individuals with a diagnosis of Alzheimer's disease and clinically significant agitation/aggression as assessed by the Neuropsychiatric Inventory (NPI), and not residing in a skilled nursing or long-term acute care facility may be eligible to participate. Enrolled participants will receive 3 weeks of psychosocial intervention (counseling). Those responding to counseling will be monitored on usual care. Those not responding to 3 weeks of counseling will randomly be assigned to receive daily escitalopram or placebo (a pill with no active ingredients) while continuing to receive counseling. These 2 groups will be compared to the group responding to counseling alone.

Location: AD-CARE - located at Monroe Community Hospital, 435 East Henrietta Rd., Rochester, NY 14620
Study Reference #: 70324

Lead Researcher (Principal Investigator)

Lead Researcher: Anton Porsteinsson

Study Contact Information

Study Coordinator: Susan Salem-Spencer, RN, MSN
Phone: (585) 760-6550

Additional Study Details

Study Details:
The study will last about 6 months. This will include 6 clinic visits for the first 4 months and 7 scheduled telephone calls spread throughout the study. You will be asked questions about your health, behavior, and memory; blood samples will be taken; and you will be asked to take simple paper and pencil tests of memory and thinking. Your caregiver will be asked questions about your health and memory. Counseling will be provided for both you and your caregiver to help understand and manage your agitation and Alzheimer's disease.

Number of Visits:  6 to 10
Parking:  Free
Transportation Coverage: 
Reimbursement:  No

Learn More About These Conditions

More information about Alzheimer's disease

Want to participate in this study?

This field is required
This field is required
You must agree to be contacted to continue.

Return to Search